Epstein-Barr infection: Current treatment options

Annals of Tropical Medicine and Public Health

Volumn 6, Issue 1, 2013, Pages 10-13

  Yaro, Abubakar ^a,b  

^a BICC Research Organization   (United Kingdom)

^b Viva Pharmaceutical Ltd   (Ghana)

Author keywords

Antiviral drugs; Epstein Barr virus infection; resistance; treatment

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARGININE BUTYRATE; ARGININE DERIVATIVE; BAY 571293; BIL 22BS; BIOLOGICAL MARKER; CIDOFOVIR; ETOPOSIDE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; NUCLEOTIDYLTRANSFERASE INHIBITOR; PENCICLOVIR; RITUXIMAB; ROMIDEPSIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ANTIBIOTIC THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL ASSESSMENT; CROSS RESISTANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FATIGUE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERACTIVITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; IRRITABILITY; MEDLINE; NUCLEIC ACID AMPLIFICATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS; REVIEW; SCREENING TEST; SEPSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT INDICATION; VIRUS LOAD; VIRUS STRAIN;

EID: 84882240559     PISSN: 17556783     EISSN: 09746005     Source Type: Journal    
DOI: 10.4103/1755-6783.115167     Document Type: Review

References (50)

1. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of Epstein-Barr virus-related diseases: A pictorial review. Jpn J Radiol 2009;27:4-19.
2. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-24.
3. Shackelford J, Pagano JS. Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem 2007;8 Suppl 1:S8.
4. Lünemann JD, Kamradt T, Martin R, Münz C. Epstein-Barr virus: Environmental trigger of multiple sclerosis? J Virol 2007;81:6777-84.
5. Virley DJ. Developing therapeutics for the treatment of multiple sclerosis. Neuro Rx 2005;2:638-49.
6. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983;40:406-8.
7. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005;293:2496-500.
8. Tarbouriech N, Ruggiero F, de Turenne-Tessier M, Ooka T, Burmeister WP. Structure of the Epstein-Barr virus oncogene BARF1. J Mol Biol 2006;359:667-78.
9. Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996;154:1712-7.
10. Filipovich AH, Gross TG, Conley ME, Pracher E, Vowels M, Williams LL, et al (1996): Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): Report from the XLP registry; Bone Marrow Transplant, 17:741-4.
11. Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: Orthotopic liver transplantation and review of the literature. Liver Transpl Surg 1998;4:469-76.
12. Herbst JS, Morgan J, Raab-Traub N, Resnick L. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia. J Am Acad Dermatol 1989;21:753-6.
13. Newman C, Polk BF. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Ann Intern Med 1987;107:348-50.
14. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114-28.
15. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-33.
16. Copur MS, Deshpande A, Mleczko K, Norvell M, Hrnicek GJ, Woodward S, et al. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Croat Med J 2005;46:458-62.
17. Pagano JS. Epstein-Barr virus: Therapy of active and latent infection. In: Jeffries DJ, De CE, editors. Antiviral Chemotherapy. Colchester, England: John Wiley and Sons Ltd.; 1995. p. 155-95.
18. Bossolasco S, Falk KI, Ponzoni M, Ceserani N, Crippa F, Lazzarin A, et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIVrelated primary central nervous system lymphoma. Clin Infect Dis 2006;42:e21-5.
19. Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, Wasik MA, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005;105:994-6.
20. Afshar K, Rao AP, Patel V, Forrester K, Ganesh S. Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient. J Transplant 2011;2011:919651.
21. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571-8.
22. Polilli E, Sozio F, Mazzotta E, Consorte A, Di Masi F, Agostinone A, et al. Rapidly progressive and fatal EBV-related encephalitis in a patient with advanced HIV-1 infection at presentation: A case report and review of the literature. New Microbiol 2010;33:275-80.
23. Hierro L, Díez-Dorado R, Díaz C, De la Vega A, Frauca E, Camarena C, et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008;14:1185-93.
24. Lysell J, Wiegleb Edström D, Linde A, Carlsson G, Malmros-Svennilson J, Westermark A, et al. Antiviral therapy in children with hydroa vacciniforme. Acta Derm Venereol 2009;89:393-7.
25. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica 2009;94:1618-22.
26. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-63.
27. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-5.
28. Bosman G, Langemeijer SM, Hebeda KM, Raemaekers JM, Pickkers P, van der Velden WJ. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis. Neth J Med 2009;67:364-5.
29. Wakabayashi S, Ohashi K, Hanajiri R, Kobayashi T, Yamashita T, Akiyama H, et al. Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring. Intern Med 2010;49:931-5.
30. Lee JS, Kang JH, Lee GK, Park HJ. Successful treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-94 protocol. J Korean Med Sci 2005;20:209-14.
31. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-9.
32. Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J 2011;8:421.
33. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008;198:659-63.
34. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010;1:555-7.
35. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114-28.
36. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: Natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010;54:4833-42.
37. Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: Analysis of specimens from three phase III trials. J Clin Microbiol 2010;48:3496-503.
38. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010;86:246-52.
39. Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre- Hernández J, et al. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J Antimicrob Chemother 2008;61:1044-7.
40. Choong K, Walker NJ, Apel AJ, Whitby M. Aciclovir-resistant herpes keratitis. Clin Experiment Ophthalmol 2010;38:309-13.
41. McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283:31289-93.
42. Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: A comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004;112:1036-41.
43. Wakabayashi S, Ohashi K, Hanajiri R, Kobayashi T, Yamashita T, Akiyama H, et al. Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring. Intern Med 2010;49:931-5.
44. Hierro L, Díez-Dorado R, Díaz C, De la Vega A, Frauca E, Camarena C, et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008;14:1185-93.
45. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007;29:569-73.
46. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000;11 Suppl 1:45-8.
47. Bankowski MJ, Anderson SM. Real-time nucleic acid amplification in clinical microbiology. Clin Microbiol Newsl 2004;26:9-15.
48. Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect 2004;10:190-212.
49. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006;12:460-4.
50. Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol 1999;37:1113-6.